HWN Suggests

Biktarvy: The newest integrase strand inhibitor

Integrase strand inhibitors are the newest class of antiretroviral agents on the market. They inhibit HIV replication by blocking the strand transfer step of HIV DNA integration into the host genome. Integrase inhibitors have emerged as the preferred treatment for HIV... Two double-blind, multicenter phase 3 trials showed bictegravir combined with TAF/FTC to be noninferior to standard therapy for the treatment of HIV-1 in patients who were treatment naive.

read full article

Articles of Interest

A Beginner’s Guide to Biktarvy: HIV Treatment Made Simple

This HIV medication is a single-tablet regimen that combines three different active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide. Each works in its own way to stop the virus from multiplying in your body. Over time, this helps bring your viral load down to undetectable levels. Once that happens, your risk of transmitting HIV to a sexual partner becomes virtually zero (commonly referred to as U=U, or Undetectable = Untransmittable).

Advanced Guide to Biktarvy: Everything you need to know in 2025

Biktarvy remains the best HIV treatment, offering effectiveness, convenience, and minimal side effects. As advancements in HIV treatment continue, understanding how Biktarvy fits into the evolving landscape is crucial.

Biktarvy Can Be a Good Option for Post-Exposure Prophylaxis

Study results showing that Biktarvy is convenient and well tolerated suggest that it should be added to PEP guidelines.

Biktarvy Continues to Suppress HIV Well in Long-Term Follow-Up

This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.

Biktarvy Factsheet

Biktarvy combines three antiretroviral drugs in one pill. Two of the drugs (emtricitabine and tenofovir alafenamide) are from a class of drugs known as NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors). The third drug, bictegravir, is an HIV integrase inhibitor. Each drug class works against HIV in a different way.

Biktarvy for HIV Treatment: Everything You Need to Know

Since 2018, Biktarvy has rapidly established itself as a recommended initial combination antiretroviral treatment (ARV) regimen for patients who are ARV-naive by the Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. In general, studies have shown it to be very well tolerated and just as effective when it comes to viral suppression as other combination HIV treatment regimens. As with any STR that includes Descovy, one of the benefits of being on Biktarvy is that not only is it effective in slowing down HIV, it is also useful in the treatment of hepatitis B. FTC and TAF, the two medications in Descovy, are effective in combination against hepatitis B.

Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review

Overall, this scoping review supports B/F/TAF as an efficacious, safe and tolerable regimen for both treatment-naïve and treatment-experienced PLWH. Virologic suppression in real-world studies was comparable to clinical trial data.

Exploring Novel Dosing Strategies by Reducing Once Daily Biktarvy

Investigators found that reducing the daily dose of BIC/FTC/TAF to as little as three times per week (3W), twice per week (2W), or once per week (1W) over 48 weeks was generally safe, well-tolerated, and effective in maintaining viral suppression in people with HIV (PWH).

Keep Being You

The 3 powerful medicines in BIKTARVY were designed to attack the virus right away and to work together to lower the amount of HIV in the blood to undetectable levels. According to DHHS, many patients can get to undetectable in as quickly as 8 to 24 weeks, when taking their treatment as prescribed. Some people are even able to start treatment the same day as diagnosis.

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Given its unique properties, potency, and tolerable safety profile, B/F/TAF provides offers another viable option as initial therapy or as an alternative antiretroviral therapy for the treatment of HIV infection.

When Choosing an HIV Regimen: Components Matter

BIKTARVY® is the only triple therapy STR that pairs the trusted DESCOVY® (FTC/TAF*) backbone with the power of bictegravir.

Resources

Biktarvy

BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 31 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.